Reduced Dosing Frequency With Tralokinumab Provides Sustained Improvements in Symptoms and Quality of Life Up to 1 Year in Adults With Moderate-to-Severe AD. J of Skin 2026, 10 (2), s731. https://doi.org/10.25251/26swpe94.